Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Taron-C DHA is a prescription prenatal vitamin and mineral supplement marketed by Trigen Laboratories. It is formulated to provide comprehensive nutritional support for women during pregnancy and the postnatal period. The product contains a combination of essential nutrients, including Vitamin C (ascorbic acid), Vitamin D3 (cholecalciferol), Vitamin B6 (pyridoxine), Folic Acid, Carbonyl Iron, and Docosahexaenoic Acid (DHA). DHA is an omega-3 fatty acid that plays a critical role in the development of the fetal brain and eyes. The inclusion of folic acid helps prevent neural tube defects, while iron supports the production of red blood cells to prevent maternal anemia. Taron-C DHA is typically administered as an oral capsule once daily to support maternal health and optimal fetal growth.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Taron-C DHA.